Potential pitfalls on the road to an effective HIV vaccine.
Experimental vaccines for AIDS prophylaxis are being tested in larger and higher-risk populations. Here, David Schwartz, an advocate of HIV-vaccine research and development, highlights some of the concerns that have been voiced about this strategy and presents a simple mathematical model that considers the drawbacks to vaccine-induced expansion of HIV-specific CD4+ T cells.
Schwartz
D H
DH
Dept of Immunology and Infectious Diseases, Johns Hopkins University School of Hygiene and PUblic Health, Baltimore, MD 21205.
D016915:AIDS Vaccines / Q000009:adverse effects* / Q000276:immunology; D000163:Acquired Immunodeficiency Syndrome / Q000276:immunology / Q000517:prevention & control*; D015496:CD4-Positive T-Lymphocytes / Q000276:immunology; D015658:HIV Infections / Q000276:immunology / Q000517:prevention & control*; D015497:HIV-1 / Q000502:physiology; D006801:Humans; D008954:Models, Biological; D014611:Vaccination; D014779:Virus Replication
D016915:AIDS Vaccines